Viatris Inc. (VTRS)

Market Cap	18.70B +65.3%
Revenue (ttm)	14.74B +4.4%
Net Income	-410.70M
EPS	-0.35
Shares Out	1.15B
PE Ratio	n/a
Forward PE	6.48
Dividend	$0.48 (2.95%)
Ex-Dividend Date	Aug 21, 2026

Volume	13,225,996
Open	16.30
Previous Close	16.43
Day's Range	16.13 - 16.71
52-Week Range	9.43 - 18.39
Beta	0.89
Analysts	Buy
Price Target	18.50 (+13.64%)
Earnings Date	Aug 6, 2026

About VTRS

Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering various noncommunicable and infectious diseases, including cardiovascular, CN...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1961
• Employees: 30,000
• Stock Exchange: NASDAQ
• Ticker Symbol: VTRS
• Website: https://www.viatris.com

Financial Performance

In 2025, Viatris's revenue was $14.30 billion, a decrease of -2.98% compared to the previous year's $14.74 billion. Losses were -$3.51 billion, 454.2% more than in 2024.

Analyst Summary

According to 10 analysts, the average rating for VTRS stock is "Buy." The 12-month stock price target is $18.5, which is an increase of 13.64% from the latest price.

Price Target

$18.5

(13.64% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Aug 11, 2026

Data Sources Report a data error